HUMANA INC

Humana beats earnings expectations while trimming Medicare plans, aiming to boost margins, star ratings, and investor confidence in a shifting health‑insurance landscape.

Humana Inc. delivers solid Q2 earnings, confirms $9 per‑share guidance, and expands its board to boost tech, compliance, and shareholder returns.

Humm Group’s board seat remains vacant as ASIC completes investigations, highlighting the firm’s focus on AI governance, breach protocols, and fair loan terms.

ASIC completes investigations into Humm Group’s Cards AU and commercial subsidiaries, finding governance gaps but no enforcement yet. Learn how the fintech is tightening controls and what it means for investors.

Humana’s modest share‑price rise reflects analyst‑backed growth: stronger Medicare Advantage enrollment, PBM revenue, and telehealth partnerships boosting earnings and investor confidence.

Humm Group (ASX: HUM) ends Credit Corp acquisition talks, reaffirming independent growth strategy and strong global presence in commercial lending and payments.

Humana’s share‑price surge reflects strong Medicare Advantage growth, expanding PBM revenue and digital care gains, but faces regulatory and tech‑disruption risks that investors must weigh.

Humana sells its $900 million minority stake in Gentiva Healthcare, targeting Q3‑2026, to boost capital for core growth and streamline its portfolio.

Explore HUMANA’s new Securities Trading Policy, its impact on insider trading compliance, and the HMO market trends driving growth opportunities.

Q3 2026 FinTech results show resilient growth amid market turbulence—commercial lending up 3.1%, consumer loan AUM 2.8%, and a 0.04 % NIM gain—yet regulatory costs and competitive pressures pose risks.